In cysts with a non-mucinous CEA level, analysis of KRAS or GNAS alone has been shown to reclassify 71% of cysts as BD-IPMN, thus improving our ability to detect cysts that need further investigation [12]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.